CytomX Therapeutics (CTMX) Short term Debt (2014)

CytomX Therapeutics' (CTMX) quarterly Short term Debt came in at $1.4 million in Q4 2014.

CytomX Therapeutics (CTMX) Short term Debt (2014) Analysis & Trends

CytomX Therapeutics (CTMX) has 1 years of Short term Debt data on file, last reported at $1.4 million in Q4 2014.

Quarterly Short term Debt changed N/A year-over-year to $1.4 million in Q4 2014, while the trailing twelve-month figure through Dec 2014 was $1.4 million (changed N/A YoY) and the FY2014 annual result came in at $1.4 million, changed N/A from the prior year.
Short term Debt held at $1.4 million in Q4 2014.
In the past five years, Short term Debt ranged from a high of $1.4 million in Q4 2014 to a low of $1.4 million in Q4 2014.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	CytomX Therapeutics	732.14 Mn	401.86 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2014	1.42 Mn